Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) – Equities research analysts at HC Wainwright dropped their Q3 2024 earnings per share estimates for shares of Oramed Pharmaceuticals in a research note issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.04) per share for the quarter, […]
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Free Report) – Analysts at HC Wainwright decreased their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a research report issued on Monday, May 20th. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings of ($0.04) per share for the quarter, down from […]
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Free Report)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.66 and traded as low as $2.21. Oramed Pharmaceuticals shares last traded at $2.32, with a volume of 161,057 shares traded. Wall Street Analysts Forecast Growth […]
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 789,300 shares, a decline of 19.9% from the March 15th total of 985,700 shares. Based on an average trading volume of 1,690,000 shares, the days-to-cover ratio is […]